USA - NASDAQ:CASI - KYG1933S1012 - Common Stock
ChartMill assigns a Buy % Consensus number of 83% to CASI. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-09-03 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-05-19 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-04-09 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-05-15 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-11-15 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-08-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-05-22 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2022-11-16 | BTIG | Maintains | Buy |
| 2022-11-15 | HC Wainwright & Co. | Maintains | Buy |
| 2022-08-15 | HC Wainwright & Co. | Maintains | Buy |
| 2022-06-03 | BTIG | Maintains | Buy |
| 2022-05-16 | HC Wainwright & Co. | Maintains | Buy |
| 2021-05-18 | BTIG | Initiate | Buy |
| 2021-05-14 | HC Wainwright & Co. | Maintains | Buy |
| 2021-04-26 | Mizuho | Initiate | Buy |
7 analysts have analysed CASI and the average price target is 4.08 USD. This implies a price increase of 205.62% is expected in the next year compared to the current price of 1.335.
The consensus rating for CASI PHARMACEUTICALS INC (CASI) is 82.8571 / 100 . This indicates that analysts generally have a positive outlook on the stock.
The number of analysts covering CASI PHARMACEUTICALS INC (CASI) is 7.